177 related articles for article (PubMed ID: 12800462)
1. COX-LOX inhibition: current evidence for an emerging new therapy.
Skelly MM; Hawkey CJ
Int J Clin Pract; 2003 May; 57(4):301-4. PubMed ID: 12800462
[TBL] [Abstract][Full Text] [Related]
2. Licofelone--clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis.
Alvaro-Gracia JM
Rheumatology (Oxford); 2004 Feb; 43 Suppl 1():i21-5. PubMed ID: 14752172
[TBL] [Abstract][Full Text] [Related]
3. Safety of anti-inflammatory treatment--new ways of thinking.
Brune K
Rheumatology (Oxford); 2004 Feb; 43 Suppl 1():i16-20. PubMed ID: 14752171
[TBL] [Abstract][Full Text] [Related]
4. The metabolic effects of inhibitors of 5-lipoxygenase and of cyclooxygenase 1 and 2 are an advancement in the efficacy and safety of anti-inflammatory therapy.
Celotti F; Durand T
Prostaglandins Other Lipid Mediat; 2003 Jul; 71(3-4):147-62. PubMed ID: 14518558
[TBL] [Abstract][Full Text] [Related]
5. Licofelone, a balanced inhibitor of cyclooxygenase and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis.
Vidal C; Gómez-Hernández A; Sánchez-Galán E; González A; Ortega L; Gómez-Gerique JA; Tuñón J; Egido J
J Pharmacol Exp Ther; 2007 Jan; 320(1):108-16. PubMed ID: 17015640
[TBL] [Abstract][Full Text] [Related]
6. The gastrointestinal tolerability of the LOX/COX inhibitor, licofelone, is similar to placebo and superior to naproxen therapy in healthy volunteers: results from a randomized, controlled trial.
Bias P; Buchner A; Klesser B; Laufer S
Am J Gastroenterol; 2004 Apr; 99(4):611-8. PubMed ID: 15089890
[TBL] [Abstract][Full Text] [Related]
7. Licofelone, a novel 5-LOX/COX-inhibitor, attenuates leukocyte rolling and adhesion on endothelium under flow.
Ulbrich H; Soehnlein O; Xie X; Eriksson EE; Lindbom L; Albrecht W; Laufer S; Dannhardt G
Biochem Pharmacol; 2005 Jul; 70(1):30-6. PubMed ID: 15894291
[TBL] [Abstract][Full Text] [Related]
8. Licofelone (Merckle).
Ding C; Cicuttini F
IDrugs; 2003 Aug; 6(8):802-8. PubMed ID: 12917777
[TBL] [Abstract][Full Text] [Related]
9. Superiority of the gastroduodenal safety profile of licofelone over rofecoxib, a COX-2 selective inhibitor, in dogs.
Moreau M; Daminet S; Martel-Pelletier J; Fernandes J; Pelletier JP
J Vet Pharmacol Ther; 2005 Feb; 28(1):81-6. PubMed ID: 15720519
[TBL] [Abstract][Full Text] [Related]
10. Licofelone, a dual COX/5-LOX inhibitor, induces apoptosis in HCA-7 colon cancer cells through the mitochondrial pathway independently from its ability to affect the arachidonic acid cascade.
Tavolari S; Bonafè M; Marini M; Ferreri C; Bartolini G; Brighenti E; Manara S; Tomasi V; Laufer S; Guarnieri T
Carcinogenesis; 2008 Feb; 29(2):371-80. PubMed ID: 18033773
[TBL] [Abstract][Full Text] [Related]
11. Gastrointestinal safety of novel nonsteroidal antiinflammatory drugs: selective COX-2 inhibitors and beyond.
Coruzzi G; Venturi N; Spaggiari S
Acta Biomed; 2007 Aug; 78(2):96-110. PubMed ID: 17933277
[TBL] [Abstract][Full Text] [Related]
12. [Inhibition of arachidonic acid-induced ear edema in the mouse with lipoxygenase-, cyclo-oxygenase- and dual inhibitors].
Zarnack S; Bekemeier H; Giessler AJ
Pharmazie; 1988 May; 43(5):337-8. PubMed ID: 3140256
[TBL] [Abstract][Full Text] [Related]
13. Clinical perspectives of anti-inflammatory therapy in the elderly: the lipoxigenase (LOX)/cycloxigenase (COX) inhibition concept.
Gaddi A; Cicero AF; Pedro EJ
Arch Gerontol Geriatr; 2004; 38(3):201-12. PubMed ID: 15066307
[TBL] [Abstract][Full Text] [Related]
14. The lipoxygenase-cyclooxygenase inhibitor licofelone prevents thromboxane A2-mediated cardiovascular derangement triggered by the inflammatory peptide fMLP in the rabbit.
Rotondo S; Dell'Elba G; Manarini S; Cerletti C; Evangelista V
Eur J Pharmacol; 2006 Sep; 546(1-3):95-101. PubMed ID: 16920097
[TBL] [Abstract][Full Text] [Related]
15. 5-Lipoxygenase metabolic contributions to NSAID-induced organ toxicity.
Burnett BP; Levy RM
Adv Ther; 2012 Feb; 29(2):79-98. PubMed ID: 22351432
[TBL] [Abstract][Full Text] [Related]
16. Combined lipoxygenase/cyclo-oxygenase inhibition in the elderly: the example of licofelone.
Cicero AF; Derosa G; Gaddi A
Drugs Aging; 2005; 22(5):393-403. PubMed ID: 15903352
[TBL] [Abstract][Full Text] [Related]
17. Gastrointestinal toxicity. Role of prostaglandins and leukotrienes.
Peskar BM; Kleine A; Pyras F; Müller MK
Med Toxicol; 1986; 1 Suppl 1():39-43. PubMed ID: 3547000
[TBL] [Abstract][Full Text] [Related]
18. NSAIDs, coxibs, CINOD and H2S-releasing NSAIDs: what lies beyond the horizon.
Fiorucci S; Santucci L; Distrutti E
Dig Liver Dis; 2007 Dec; 39(12):1043-51. PubMed ID: 17997373
[TBL] [Abstract][Full Text] [Related]
19. Licofelone, an inhibitor of cyclooxygenase and 5-lipoxygenase, specifically inhibits cyclooxygenase-1-dependent platelet activation.
Rotondo S; Krauze-Brzósko K; Manarini S; Evangelista V; Cerletti C
Eur J Pharmacol; 2004 Mar; 488(1-3):79-83. PubMed ID: 15044038
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs.
Martel-Pelletier J; Lajeunesse D; Reboul P; Pelletier JP
Ann Rheum Dis; 2003 Jun; 62(6):501-9. PubMed ID: 12759283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
